In a report released yesterday, Samantha Semenkow from Citi maintained a Buy rating on MoonLake Immunotherapeutics, with a price target of $72.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Samantha Semenkow’s rating is based on a combination of factors, including the potential regulatory approval for MoonLake Immunotherapeutics despite the mixed results from the Phase 3 trials of sonelokimab. The VELA program showed statistically significant results on all primary and secondary endpoints, which suggests a possible path forward for regulatory approval, even though the VELA-2 trial did not achieve statistical significance using the primary analysis method.
Furthermore, while the comparison with competitor Bimzelx shows that the VELA data may not be highly differentiated, the overall potential for MoonLake’s product to meet regulatory requirements contributes to the Buy rating. The expected share price return of 16.1% also supports the positive outlook, indicating a favorable risk-reward scenario for investors.
In another report released today, Needham also maintained a Buy rating on the stock with a $66.00 price target.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MLTX in relation to earlier this year.